RUIZ THOMAS MARK
Known title: Chief Commercial OfficerCIK: 0001768484
Associated companies
Transaction History
| INFU | ▲ Buy | Option Exercise | 10,000 | $20K | 9/1/2022 | View on chart |
| INFU | ▼ Sell | Open Market | 10,000 | $76K | 9/1/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 15,000 | $30K | 6/7/2022 | View on chart |
| INFU | ▼ Sell | Open Market | 15,000 | $148K | 6/7/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 4,391 | $37K | 5/20/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 2,064 | $18K | 5/20/2022 | View on chart |
| INFU | ▲ Buy | Grant | 4,700 | $0 | 5/20/2022 | View on chart |
| INFU | ▲ Buy | Grant | 10,000 | $0 | 5/20/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 1,389 | $12K | 5/18/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 4,240 | $36K | 5/18/2022 | View on chart |
| INFU | ▲ Buy | Grant | 9,744 | $0 | 5/18/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 2,821 | $0 | 5/18/2022 | View on chart |
| INFU | ▼ Sell | Open Market | 76 | $1K | 12/29/2021 | View on chart |
| INFU | ▲ Buy | Option Exercise | 10,000 | $0 | 11/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
INFU Shares Business Overview, Emphasizes Patient-First Strategy
INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.
INFU Shares Business Overview, Emphasizes Patient-First Strategy. INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.